ACCESS Newswire

Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings

10.2.2025 07:50:00 CET | ACCESS Newswire | Press release

Share

Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence.

"The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. History now repeats itself, except now the anti-vaccine lawyer, Kennedy, could become in charge of US science and medicine as a whole."

Eviva Partners's solution to this crisis is simple: "Evidence Fluency." The premise is that one key, previously overlooked factor underlies the current challenges of poor and unequal outcomes and rising costs in the U.S. healthcare system: insufficient "evidence fluency" among patients, providers, and other healthcare stakeholders.

"We are a nonpartisan organization committed to helping improve health outcomes for all" said Morozov.

Eviva Partners introduces the concept of "evidence fluency" as a solution to the current crisis and a path towards improving healthcare overall, defined as having four components:

  • Understanding the concept of evidence as distinct from "proof;"

  • Ability to assess the strength of evidence;

  • Ability to detect manipulation;

  • Ability to discuss evidence with others.

Eviva Partners will focus on three areas:

  1. Pioneering deep characterization of care gaps (both underuse and overuse), starting in hematology-oncology care, at the state level;

  2. Developing a multi-pronged approach to increase evidence fluency through:

    • "Two-Eyed Seeing" methodology for bridging worldviews

    • K-12 evidence curriculum

    • A tool kit for patients and providers

  3. Creating state and federal policy proposals to improve healthcare transparency and quality, starting with protecting the integrity of scientific literature.

The organization has assembled a distinguished advisory council including Elder Albert Marshall of the Mi'kmaw Nation, creator of the "Two-Eyed Seeing" methodology; Stephan Lewandowsky, a leading cognitive scientist at the University of Bristol, and others.

"Our preliminary surveys show that only 16% of U.S. adults correctly understand the difference between evidence and proof, while 36% have never heard the word 'evidence' used in a medical context," said Morozov. "By improving evidence fluency across the healthcare ecosystem, we can help close care gaps and ultimately improve health outcomes for all."

Initial pilot studies will focus on sickle cell disease and cancer, where care gaps are high. In addition, K-12 evidence curriculum will be piloted. Once those are completed, the organization plans to launch a nationwide public awareness campaign to promote evidence fluency.

For more information about Eviva Partners, and to read Alex Morozov's expose, "Robert F. Kennedy Jr, Andrew Wakefield and The Manufacture of Evidence," visit www.evivapartners.org, or follow Eviva Partners on Twitter, BlueSky, LinkedIn, Facebook and Instagram.

Contact Information

Alex Morozov
CEO and Founder
alex.morozov@evivapartners.org
9173751112

SOURCE: Eviva Partners



View the original press release on ACCESS Newswire

Eviva Partners

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Fermi Announces Binding Lease Agreement with TensorWave10.8.2026 23:10:00 CEST | Press release

Intends to grow the partnership to more than 650 megawatts (MW) over three phases First phase to deliver a complete turnkey data center solution with 222 MW beginning in the second half of 2027, representing approximately $6.5 billion in total contracted revenue Fermi and TensorWave have lined up world-class partners to collaborate on the project and expect certain of the obligations under the lease to be guaranteed by one of the global leaders in AI DALLAS, TX / ACCESS Newswire / August 10, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it has executed its first binding customer lease at its Project Matador campus in Carson County, Texas. The lease between Fermi's subsidiary Fermi Campus 1 LLC and TensorWave TEX1, LLC, a subsidiary of AI cloud provider TensorWave Inc., covers a facility supported by 222 megawatts (MW) of total facility power following commencement of the final delivery phase. Once fully delivered

Juno International Corporation Acquires Securities of Rocky Shore Gold Ltd.10.8.2026 23:10:00 CEST | Press release

TORONTO, ON / ACCESS Newswire / August 10, 2026 / Juno International Corporation (formerly Northfield Capital Corporation) (the "Acquiror") announces that it acquired ownership and control of 1,549,000 common shares (the "Subject Shares") of Rocky Shore Gold Ltd. (the "Company") on July 24, 2026 through the facilities of the Canadian Securities Exchange, representing approximately 0.65% of all issued and outstanding common shares of the Company as of such date immediately following such transaction. Immediately before the transaction described above, the Acquiror held an aggregate of 40,569,188 common shares of the Company and common share purchase warrants entitling the Acquiror to acquire an additional 5,180,000 common shares of the Company (the "Warrants"), representing approximately 17.11% of the issued and outstanding common shares of the Company on a non-diluted basis (or approximately 18.88%, on a partially diluted basis, assuming exercise of the Warrants only). Upon completion

Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement10.8.2026 20:30:00 CEST | Press release

Not for distribution to United States newswire services or for dissemination in the United States. THUNDER BAY, ON / ACCESS Newswire / August 10, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) and Springbok Ventures Inc. ("Springbok") are pleased to announce that, further to the joint news release dated August 1, 2026, due to strong market demand they have agreed to increase the size of the previously announced non-brokered private placement of subscription receipts (the "Offering") to $6.1 million, as follows: 10,000,000 subscription receipts of Springbok (the "Springbok Subscription Receipts") at a price of $0.50 per Springbok Subscription Receipt; and 2,000,000 subscription receipts of Clean Air Metals (the CAM Subscription Receipts") at a price of $0.55 per CAM Subscription Receipt. Each Springbok Subscription Receipt will, subject to satisfaction or waiver of certain escrow release conditions, automatically convert in accordance with its terms

ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release

ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia

Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release

Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye